היקמטין 0.25 מג
novartis israel ltd - topotecan as hydrochloride - קפסולות ג'לטין קשיחות - topotecan as hydrochloride 0.25 mg - topotecan - topotecan - indicated for the treatment of patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.
היקמטין 1 מג
novartis israel ltd - topotecan as hydrochloride - קפסולות ג'לטין קשיחות - topotecan as hydrochloride 1 mg - topotecan - topotecan - indicated for the treatment of patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.
היקמטין iv
novartis israel ltd - topotecan as hydrochloride - אבקה להכנת תמיסה לאינפוזיה - topotecan as hydrochloride 4 mg/vial - topotecan - topotecan - treatment of metastatic carcinoma of the ovary after failure of initial or subsequent therapy. treatment of small cell lung cancer sensitive disease after failure of first line chemotherapy. topotecan in combination with cisplatin is indicated for the treatment of stage iv-b recurrent or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy.
פוטאקטזול 1 מ"ג
devries & co. ltd - topotecan hydrochloride 1 mg - powder for concentrate for soution for infusion - topotecan - treatment of metastatic carcinoma of the ovary after failure of initial or subsequent therapy. treatment of small cell lung cancer sensitive disease after failure of first line chemotherapy. topotecan in combination with cisplatin is indicated for the treatment of stage iv-b recurrent or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy.
טופוטקן מדיסון 4 מג'
medison pharma ltd - topotecan hydrochloride 4 mg/vial - powder for concentrate for infusion - topotecan - treatment of metastatic carcinoma of the ovary after failure of initial or subsequent therapy.treatment of small cell lung cancer sensitive disease after failure of first line chemotherapy. topotecan in combination with cisplatin is indicated for the treatment of stage iv-b recurrent or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy.
טרודלווי
gilead sciences israel ltd - sacituzumab govitecan - sacituzumab govitecan 200 mg
אווסטין
roche pharmaceuticals (israel) ltd - bevacizumab - תרכיז להכנת תמיסה לאינפוזיה - bevacizumab 25 mg/ml - bevacizumab - bevacizumab - avastin in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic carcinoma of the colon or rectum.avastin in addition to platinum - based chemotherapy is indicated for first - line treatment of patients with unresectable advanced metastatic or recurrent non- small cell lung cancer other than predominantly squamous cell histology. avastin in combination with interferon alfa-2a is indicated for first line treatment of patients with advanced and /or metastatic renal cell cancer. avastin in combination with paclitaxel is indicated for first-line treatment of patients with metastatic breast cancer.avastin as asingle agent, is indicated for the treatment of glioblastoma in patients with progressive disease following prior therapy.avastin, in combination with carboplatin and paclitaxel, is indicated for the front-line treatment of advanced (figo stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are at hig
אמווסי
amgen europe b.v. - bevacizumab - תרכיז להכנת תמיסה לאינפוזיה - bevacizumab 25 mg / 1 ml - bevacizumab
קייליקס
j-c health care ltd - doxorubicin hydrochloride - liposome for infusion - doxorubicin hydrochloride 2.0 mg/ml - doxorubicin - doxorubicin - first or second line therapy of aids related kaposis sarcoma in patients with low cd 4 counts and extensive mucocutaneous or visceral disease the treatment of patients with metastatic carcinoma of the ovary who are refractory to both paclitaxel and platinium-based chemotherapy regimens and who may also be refractory to topotecan. refractory is defined as a patient having progressive disease while on treatment or within 6 months of completing treatmnt. as monotherapy for patients with metastatic breast cancer where there is an increased cardiac risk. in combination with bortezomib for the treatment of progressive multiplemyeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.